HK Stock MarketDetailed Quotes

02126 JW THERAP-B

Watchlist
  • 1.420
  • -0.040-2.74%
Not Open Nov 12 16:08 CST
589.92MMarket Cap-857P/E (TTM)

About JW THERAP-B Company

Pharmaceutical Ming Junuo (Hong Kong Stock Exchange Code: 2126) is an independent and innovative biotechnology company that focuses on developing, producing and commercializing cellular immunotherapy products, and is committed to leading innovation to become a leader in cellular immunotherapy. Established in 2016, Pharmaceutical MingJunuo has successfully built the world's leading comprehensive product development platform for cellular immunotherapy, as well as a cellular immunotherapy product pipeline covering hematologic tumors, solid tumors, and autoimmune diseases. Pharmaceutical Ming Junuo is committed to bringing hope for healing to patients in China and the world with breakthrough, high-quality cellular immunotherapy products, and leading the development of health standards in China's cellular immunotherapy industry.

Company Profile

Symbol02126
Company NameJW THERAP-B
ISINKYG5210T1040
Listing DateNov 3, 2020
Issue Price23.80
Shares Offered97.69M share(s)
FoundedSep 6, 2017
Registered AddressCayman Islands
Chairmanyiping li
Secretaryjiawen wu
Audit InstitutionDeloitte Guan Huang Chen Fang Certified Public Accountants
Company CategoryOther
Registered OfficePO Box 309, Ugland House Grand Cayman, KY1—1104 Cayman Islands
Head Office and Principal Place of Business31st Floor, Tower 2, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees323
MarketHong Kong motherboard
Phone(86)2150783699
Websitehttp://www.jwtherapeutics.com/
Business Pharmaceutical Junuo (Cayman) Co., Ltd. is a company mainly engaged in research and development, production and marketing of cellular immunotherapy products. The company has established an integrated platform for the development of cellular immunotherapy products and a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. The company's main product, Benodat, is an autologous CAR-T cell immunotherapy product targeting CD19 developed independently on the basis of Juno (a Bristol-Myers Squibb company) chimeric antigen receptor T cell (CAR-T) cell processing platform. The company mainly operates in the domestic market.

Company Executives

  • Name
  • Position
  • Salary
  • min liu
  • CEO, Executive Director, Strategy Committee Members, Nomination Committee Members, Authorized Representative
  • --
  • yiping li
  • Presidencies, Non-executive Directors
  • 31.12M
  • xing gao
  • Non-executive Directors, Audit Committee Members, Strategy Committee Members
  • --
  • Sungwon Song
  • Non-executive Directors, Remuneration Committee Members
  • --
  • cheng liu
  • Non-executive Directors
  • 331.00K
  • jianchang he
  • Independent Non-Executive Director, Chairman of the Nomination Committee, Chairman of the Audit Committee
  • 224.00K
  • jiuyun yu
  • Independent Non-Executive Director, Chairman of the Strategy Committee, Remuneration Committee Chairman, Nomination Committee Members
  • --
  • bingjun chen
  • Independent Non-Executive Director, Remuneration Committee Members, Audit Committee Members
  • --
  • qiang ma
  • Senior Vice President, Chief Commercial Officer
  • --
  • Shaun Paul Cordoba
  • Senior Vice President, Chief Scientific Officer
  • --
  • yun qin
  • Senior Vice President
  • --
  • su yang
  • Executive Director of Clinical Research and Development
  • --
  • jiawen wu
  • Authorized Representative, Company Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data